Perrigo Company PLC (PRGO)
| Market Cap | 5.74B |
| Revenue (ttm) | 5.06B |
| Net Income (ttm) | -162.60M |
| Shares Out | 133.57M |
| EPS (ttm) | -1.20 |
| PE Ratio | n/a |
| Forward PE | 16.18 |
| Dividend | $0.90 |
| Dividend Yield | 2.09% |
| Trading Day | May 7 |
| Last Price | $42.96 |
| Previous Close | $42.65 |
| Change ($) | 0.31 |
| Change (%) | 0.73% |
| Day's Open | 42.69 |
| Day's Range | 42.58 - 43.46 |
| Day's Volume | 761,029 |
| 52-Week Range | 37.98 - 57.97 |
You may not have heard of Perrigo, but it's a stellar dividend stock, and one that income investors should make sure to watch. The post Undervalued Perrigo Is A Dividend Stock to Have And to Hold appear...
DUBLIN, April 27, 2021 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality, Affordable Self-Care Products, today announced that it will release its fiscal first quarter...
Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.
Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DUBLIN, April 19, 2021 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality, Affordable Self-Care Products, today announced that its Board of Directors declared a...
We believe that Perrigo stock, a healthcare company that provides over-the-counter self-care products, including generic drugs and consumer products, is a good buying opportunity at the present time. PR...
Perrigo (PRGO) reports dismal fourth-quarter 2020 results. The company signs deal to sell its generic drug business for $1.55 billion.
Perrigo (PRGO) delivered earnings and revenue surprises of -7.92% and -2.81%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Perrigo Company Plc (NYSE: PRGO) has agreed to sell its Generic Rx Pharmaceuticals business to Altaris Capital Partners for $1.55 billion. The price included a $1.5 billion payment in cash.
Shares of Perrigo (NYSE:PRGO) rose 0.6% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 12.26% over the past year to $0.93, which missed the estima...
DUBLIN, Feb. 23, 2021 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality, Affordable Self-Care Products, announced today that its Board of Directors approved a ...
Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be-reported quarter.
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying can b...
We believe that Perrigo stock, a healthcare company that provides over-the-counter health and wellness solutions, is a good buying opportunity at the present time. PRGO stock trades near $45 currently a...
Let's see if Perrigo Company plc (PRGO) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock?
In its journey to become a consumer-led player, Perrigo has already achieved its long-term sales targets well ahead of the schedule. Partly helped by pandemic-driven changes to consumer habits, the high...
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment ...
Investors liked the company's third-quarter earnings results.
Perrigo (PRGO) reports decent third-quarter 2020 results. U.S. consumer self-care segment drives sales.
The healthcare company delivered both good news and bad news.
Perrigo Company plc (PRGO) CEO Murray Kessler on Q3 2020 Results - Earnings Call Transcript
Perrigo (PRGO) delivered earnings and revenue surprises of 10.71% and -1.44%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
DUBLIN, Nov. 4, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that the Irish High Court, which is a court of first instance, ruled that the issuance of the Notice of Amende...
DUBLIN, Nov. 2, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality, Affordable Self-Care Products, announced today that it has completed the acquisition of...
DUBLIN, Oct. 29, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality, Affordable Self-Care Products, today announced that it has been advised by the Irish High Cou...
Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be-reported quarter.
Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DUBLIN, Oct. 22, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality, Affordable Self-Care Products, today announced that its Board of Directors declared a ...
DUBLIN, Oct. 14, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality, Affordable Self-Care Products, today announced that it will release its third quarter financi...
Perrigo Company plc shares PRGO, -0.16% slid 3% in premarket trade Thursday, after the company said it's voluntarily recalling albuterol sulfate inhalation aerosols over concerns that some may not dispe...
DUBLIN, Sept. 17, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced a voluntary U.S.
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock?
DUBLIN, Ireland, Aug. 25, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality, Affordable Self-Care Products, today announced that CEO and President, Murray S.
Perrigo Company plc (PRGO) CEO Murray Kessler on Q2 2020 Results - Earnings Call Transcript
Perrigo (PRGO) reports decent second-quarter 2020 results. The addition of products following Ranir acquisition boosts sales in the quarter.
Perrigo (PRGO) delivered earnings and revenue surprises of 18.39% and -0.69%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Perrigo (NYSE:PRGO) rose 0.9% in pre-market trading after the company reported Q2 results.
Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Perrigo Company PLC (NYSE: PRGO), one of the world’s largest producers of over-the-counter self-care products, is entering the CBD business.
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock?
PRGO can effectively and cost efficiently produce generic drugs, competing with brand names.
Perrigo Company plc (PRGO) CEO Murray Kessler on Q1 2020 Results - Earnings Call Transcript
Perrigo (PRGO) reports decent first-quarter 2019 results. The addition of products following Ranir acquisition and stock piling due to COVID-19 boosts sales in the quarter.
Perrigo (PRGO) delivered earnings and revenue surprises of 4.59% and 1.51%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
About PRGO
Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through Consumer Self-Care Americas, Consumer Self-Care International, and Prescription Pharmaceuticals segments. The Consumer Self-Care Americas segment focuses primarily on the development, manufacture, marketing, and sale of store brand, self-care products in categories, including upper respiratory, pain and sleep-aids, digest... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | IPO Date Dec 16, 1991 |
| CEO Murray Kessler | Employees 11,500 |
| Stock Exchange NYSE | Ticker Symbol PRGO |
Analyst Forecasts
According to 11 analysts, the average rating for Perrigo stock is "Buy." The 12-month stock price forecast is 54.13, which is an increase of 26.00% from the latest price.